Search Results

Adolore BioTherapeutics, a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, announced that it will present at the Virtual Investor Pitch Conference on June 17, 2024 at 10:00 AM ET.

Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today outlined recent pipeline development progress and provided a business outlook.

Adolore BioTherapeutics (“Adolore” or the “Company”), a company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced that Roelof Rongen, CEO of Adolore, will participate at the Virtual Investor Ask the CEO Conference on Wednesday, October 25, 2023 at 3:00 PM ET.

Adolore BioTherapeutics (“Adolore” or the “Company”) today announced that Roy C. Levitt, MD, the Company’s founder and Executive Chairman, Clinical Professor, University of Miami, and Principal Investigator of a NIH, NINDS, HEAL UH3 Award will present at the 5th Annual NIH HEAL Initiative Scientific Meeting being held February 7-8, 2024 in Bethesda, Maryland.

Adolore BioTherapeutics (“Adolore” or the “Company”), a biotechnology company focused on developing breakthrough opioid-free gene therapy treatments for chronic pain, today announced the U.S. Patent and Trademark Office (USPTO) has issued patent No. 11,911,450 covering its innovative CA8* (*Carbonic anhydrase-8-like analgesic peptides, CA8 variants) gene therapies, using a state-of-the-art replication-defective disease-free HSV vector (rdHSV-CA8*).